www.aastocks.com
2026-06-15
HBM Holdings (02142.HK) saw its stock price rise over 5% following a favorable ruling in a U.S. patent infringement lawsuit. The case, initiated in 2021 by Harbour Antibodies, a subsidiary of HBM Holdings, against Amgen and its affiliate Teneobio, resulted in a jury verdict finding willful infringem